Medical Condition News

RSS

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

K2M launches VIKOS Cervical Allograft System

K2M, Inc., the spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced the launch of its first product in the spinal biologics market, the VIKOS™ Cervical Allograft System. K2M worked with LifeNet Health™, a leading allograft bio-implant and regenerative medicine company, to combine quality machined allograft implants with precision instrumentation.

1 Oct 2010

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

CDC awards ACS and GWCI $4.25 million to establish National Cancer Survivorship Resource Center

The American Cancer Society (ACS) and the GW Cancer Institute (GWCI) were recently awarded $4.25 million by the Centers for Disease Control (CDC) to establish a National Cancer Survivorship Resource Center. Work on the project will begin on September 30.

1 Oct 2010

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®.

1 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

A new report published in the October 2010 print issue of The FASEB Journal offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems could be potent drug targets in the effort to stop cancer. In addition, their hypothesis provides new insights into what contributes to immunological disorders such as chronic inflammation and autoimmune diseases.

1 Oct 2010

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.

1 Oct 2010

Report finds development of multiple myeloma is tied to 'hypomethylation'

DNA methylation - a modification of DNA linked to gene regulation - is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

The University of Alabama at Birmingham Comprehensive Cancer Center, in collaboration with the University of Minnesota, has won an $11.5 million grant from the National Cancer Institute to explore groundbreaking pancreatic cancer research, prevention and treatment.

1 Oct 2010

FDA takes action against unapproved single-ingredient oral colchicine

The U.S. Food and Drug Administration took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).

1 Oct 2010

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study.

1 Oct 2010

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Headaches, back pain, arthritis and other aches distract employees and cost companies more than $61 billion a year in lost productive time, according to a study published in the Journal of the American Medical Association.

1 Oct 2010

CSHL professor receives NIH grant to study mechanism behind autism and schizophrenia

Anthony Zador, Ph.D., Professor of Biology and Program Chair in Neuroscience at Cold Spring Harbor Laboratory (CSHL), has been awarded a $2.17 million, 5-year grant by the National Institutes of Health (NIH)'s Transformative Research Projects Program (T-R01).

1 Oct 2010

Researchers discover key leukemia defense mechanism

Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs).

1 Oct 2010

Family and friends may pose the greatest threat to caregivers' health and well-being

The biggest cause of stress for people who care for loved ones after a stroke may not be worrying about the affected family member.

1 Oct 2010

South Asian ethnicity is a risk factor for cardiovascular events after renal transplantation

Ethnicity is a contributing risk factor of cardiovascular problems in kidney recipients of South Asian origin post-transplant, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

1 Oct 2010

Medical Condition News

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

K2M launches VIKOS Cervical Allograft System

Increase in levels of P450 protein creates EET molecules that lower blood pressure

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

CDC awards ACS and GWCI $4.25 million to establish National Cancer Survivorship Resource Center

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

FDA issues Complete Response Letter for Teva's Neutroval BLA

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

Report finds development of multiple myeloma is tied to 'hypomethylation'

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

FDA takes action against unapproved single-ingredient oral colchicine

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Headaches, back pain and arthritis cost companies more than $61 billion per annum

CSHL professor receives NIH grant to study mechanism behind autism and schizophrenia

Researchers discover key leukemia defense mechanism

Family and friends may pose the greatest threat to caregivers' health and well-being

South Asian ethnicity is a risk factor for cardiovascular events after renal transplantation

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News